NL-OMON45101已完成3 期
Optimizing DMARD therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome - LEF/HCQ combination therapy for pSS
niversitair Medisch Centrum Utrecht0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64(—)
入选标准
- •1) Women and men, 18-75 years
- •2) Primary Sjogren's Syndrome diagnosed according to the American-European Consensus Criteria, revised in 2002
- •3) Lymphocyte focus score (local lymphocytic infiltrates) *1 in sublablial salivary gland specimen
- •4) ESSDAI * 5
- •5) Use of a reliable method of contraception
- •6) Signed written informed consent
排除标准
- •1) Pregnancy or the wish to conceive (also for men) during the study or within 2 years after the study
- •2) Breastfeeding
- •3) Therapy resistant hypertension
- •4) Maculopathy or retinitis pigmentosa
- •5) Secondary Sjogren*s Syndrome
- •6) Hepatic or renal impairment
- •7) Severe infection (including hepatitis B,C or HIV)
- •8) Malignancy other than mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)
- •9) Significant cytopenia
- •10) Concomitant heart- and inflammatory bowel disease
- •11) Sarcoidosis
- •12) Usage of HCQ or LEF <6 months year prior to inclusion
- •13) Usage of immunosuppressive drugs, with the exception of a stable dose of non- steroidal inflammatory drugs (NSAID's) and a stable, low dose (*7.5 mg) of oral corticosteroids
- •14) Inadequate mastery of the Dutch language;Exclusion criteria for imaging part (MRI and PET/CT)
- •1. A history of allergy/hypersensitivity to radio-isotopes or gadolinium-containing contrast agents
- •2. A fasting blood glucose level of >11 mmol/L at screening
- •3. Standard safety procedures for MRI will be applied, for example patients with metal or internal medical devices within their body will be excluded;Patients that meet any of the exclusion criteria for the imaging part of the study will be excluded only from this part of the study. If that patient does meet criteria for inclusion in the main study, she can still participate to this main part.
研究者
相似试验
进行中(未招募)
不适用
eflunomide and Hydroxychloroquine combination therapy for primary Sjogren's SyndromeSjogren's SyndromeEUCTR2014-003140-12-NLMC Utrecht
进行中(未招募)
Unknown
Stratified medicine in primary Sjogren’s syndromeISRCTN16054712ewcastle upon Tyne Hospitals NHS Foundation Trust600
尚未招募
不适用
Runzaoyin in the treatment of primary Sjogren's syndrome Clinical observation of spleen deficiency and fluid deficiency syndromeprimary Sjogren's syndromeITMCTR2200005628Xiyuan Hospital, Chinese Academy of traditional Chinese medical science
尚未招募
不适用
Standardization study of Sjogren's syndrome based on epidemiological investigation and cohort studySjogren's syndromeITMCTR1900002438Chongqing Hospital of Traditional Chinese Medicine
已完成
1 期
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infection (COVID-19)Patients with Severe Pneumonia caused by SARS-CoV-2 infectionJPRN-jRCT1080225320ROHTO PHARMACEUTICAL CO., LTD.6
